MeiraGTx Q2 FY26 net income swings to USD 160.7 million; revenue jumps to USD 321.4 million - MGTX News | RalliesMeiraGTx Q2 FY26 net income swings to USD 160.7 million; revenue jumps to USD 321.4 million
M
MGTX• Quarterly results and pipeline updates
- MeiraGTx swung to net income of $160.7 million, or $1.76 per share, in Q2 2026 from a net loss.
- Revenue climbed to $321.4 million from $3.7 million, driven by $204.6 million license revenue and $104.9 million related-party service revenue.
- R&D expenses rose 72.54% to $57.8 million, while cash and cash equivalents increased to $143.2 million from $65.9 million at year-end 2025.
- Completed $25 million reacquisition of bota-vec from J&J, targeting global regulatory filings in 2026 ahead of a potential 2027 launch.
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1; pivotal Phase 2 enrollment finished, with 12-month data expected in Q2 2027.
•
